- Research Grants
graduation at Biotecnologia from Universidade Estadual Paulista Júlio de Mesquita Filho (2008) and master's at Pharmacy from Universidade de São Paulo (2011). Has experience in Biochemistry, focusing on Molecular Biology, acting on the following subjects: cultura de células, equivalente dérmico, mini-gene, terapia gênica and melanoma b16f10. (Source: Lattes Curriculum)
Human melanoma presents extreme chemoresistance and poor prognosis with a higher risk of lymphatic and hematogenous metastases, besides six to nine months of survival rate. There is no drug efficient in spite of recent advances in therapy as the verumafenib and ipilimumab, since the patients have still shown chemoresistance and tumor recurrence. The current treatment, therefore, is stil...
Human melanoma presents extreme chemoresistance and poor prognosis with a high risk of lymph node metastasis, hematogenous, and survival rate of six to nine months. Vemurafenib (PLX4032) caused great impact on therapeutic power because it was capable of inducing arrest of cell cycle and apoptosis , in addition to inhibiting the proliferation exclusively V600E positive cells in vitro sys...
(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)
|Data from Web of Science|